|(Sempermed)______|______________________|__________|________|__________| 
|_________________|EBITDA________________|220.5_____|>100%___|23.0______| 
|_________________|EBIT__________________|210.6_____|+90.2%__|110.7_____| 
 
 
 
 
1) Adjusted for the positive one-off effect from the impairment reversal in the 
Sempermed segment (H1 2020: EBIT effect: EUR +88.8 million; earnings after tax 
effect: EUR +94.1 million) and for the negative one-off effect of the impairment 
in the Sempertrans segment (H1 2020: EBIT effect EUR -20.0 million; earnings 
after tax effect: EUR -16.3 million) 
 
For further details please refer to the half-year report 2021 of the Semperit 
Group. 
 
 
 
 
Further inquiry note: 
Monika Riedel 
Director Group Brand Management, Corporate Spokesperson 
+43 676 8715 8620 
monika.riedel@semperitgroup.com 
 
Judit Helenyi 
Director Investor Relations 
+43 676 8715 8310 
judit.helenyi@semperitgroup.com 
 
www.semperitgroup.com 
 
end of announcement                         euro adhoc 
=-------------------------------------------------------------------------------

(END) Dow Jones Newswires

August 19, 2021 01:41 ET (05:41 GMT)